Replicate Bioscience Announces Publication of First-in-Human Data for Its Optimized srRNA Rabies Vaccine in Nature Communications

Results provide clinical demonstration of best-in-class immunogenicity achieved with an RNA-based platform and good tolerability RBI-4000's potential to offer a meaningful improvement over existing vaccines for rabies, an ongoing global public health concern, supports further development...